Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Inhibrx Biosciences Inc. (INBX)
USD91.44
-1.77 (-1.90%)
US NASDAQ Healthcare Biotechnology
Address
11025 North Torrey Pines Road 92037
La Jolla, CA, US
La Jolla, CA, US
CEO
Mark Lappe
Website
inhibrx.com
IPO
2024-05-29
CIK 2007919 ISIN US45720N1037
Also trades on
NASDAQ Global Market · INBX (USD)
NASDAQ Global Market · INXB (USD)
Description
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
News Sentiment (7d)
Based on only 1 article — low confidence
- Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice Zacks Investment Research
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD91.44
-1.77 (-1.90%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
453.1K
Beta
3.32
Float Shares
10.87M
Free Float %
74.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.43% | +3.43% | -20.63% | +34.13% | +15.87% | +16.71% | +530.64% | +242.88% | +277.25% | +346.92% | +346.92% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
91.44
Low
325.00
+255.4%
Consensus
325.00
+255.4%
Median
325.00
+255.4%
High
325.00
+255.4%
DCF (Unlevered)
0.72
-99.2%
DCF (Levered)
0.78
-99.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
67% Bullish
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
325.00
+255.4%
|
| Last Quarter | 1 |
325.00
+255.4%
|
| Last Year | 1 |
325.00
+255.4%
|
| All Time | 1 |
325.00
+255.4%
|
Quality scores
Altman Z-Score
0.64
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+550.0% ★
-
EPS growth Biotechnology: +29.7%-107.8% Q1'26: +23.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-11,721.9%
-
EBIT margin Biotechnology: +0.0%-10,386.5%
-
ROIC Biotechnology: -16.1%— Q1'26: +70.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+7.0% Q1'26: +0.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.81× Q1'26: -0.05× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
12.81M
est: 11.10M (+15.4%)
|
7.13M
est: 6.10M (+16.8%)
|
2.19M
est: 2.60M (-15.7%)
|
1.80M
est: 1.78M (+1.0%)
|
200.0K
est: 100.0K (+100.0%)
|
1.30M
est: 1.30M (+0.0%)
|
4.30M
3.37M – 5.23M
+230.8% YoY
|
57.20M
28.58M – 85.81M
+1,230.2% YoY
|
131.35M
102.83M – 159.85M
+129.6% YoY
|
202.56M
158.58M – 246.51M
+54.2% YoY
|
353.60M
276.84M – 430.33M
+74.6% YoY
|
| EBITDA |
-63.80M
est: -6.66M (-857.9%)
|
-75.37M
est: -79.79M (+5.5%)
|
-125.82M
est: -90.24M (-39.4%)
|
-206.69M
est: -1.07M (-19,220.7%)
|
1.70B
est: -60.0K (+2,839,016.7%)
|
-132.54M
est: -780.0K (-16,892.6%)
|
-2.58M
-3.14M – -2.02M
-230.8% YoY
|
-34.32M
-51.48M – -17.15M
-1,230.2% YoY
|
-78.81M
-95.91M – -61.70M
-129.6% YoY
|
-121.53M
-147.91M – -95.15M
-54.2% YoY
|
-212.16M
-258.20M – -166.10M
-74.6% YoY
|
| EBIT |
-64.82M
est: -6.66M (-873.2%)
|
-76.56M
est: -79.20M (+3.3%)
|
-127.04M
est: -89.38M (-42.1%)
|
-207.88M
est: -1.07M (-19,332.0%)
|
1.70B
est: -60.0K (+2,835,208.3%)
|
-135.03M
est: -780.0K (-17,210.9%)
|
-2.58M
-3.14M – -2.02M
-230.8% YoY
|
-34.32M
-51.48M – -17.15M
-1,230.2% YoY
|
-78.81M
-95.91M – -61.70M
-129.6% YoY
|
-121.53M
-147.91M – -95.15M
-54.2% YoY
|
-212.16M
-258.20M – -166.10M
-74.6% YoY
|
| Net Income |
-75.64M
est: -38.18M (-98.1%)
|
-81.77M
est: -84.59M (+3.3%)
|
-145.23M
est: -172.21M (+15.7%)
|
-241.36M
est: -84.20M (-186.7%)
|
1.69B
est: 1.73B (-2.3%)
|
-140.06M
est: -130.19M (-7.6%)
|
-173.62M
-183.37M – -102.66M
-33.4% YoY
|
-106.56M
-129.66M – -72.59M
+38.6% YoY
|
-67.95M
-104.38M – -18.74M
+36.2% YoY
|
-42.28M
-54.21M – -30.35M
+37.8% YoY
|
42.74M
30.68M – 54.80M
+201.1% YoY
|
| SGA |
6.84M
est: 1.48B (-99.5%)
|
12.36M
est: 814.66M (-98.5%)
|
21.12M
est: 347.23M (-93.9%)
|
29.38M
est: 244.32M (-88.0%)
|
127.91M
est: 13.70M (+833.4%)
|
23.30M
est: 178.14M (-86.9%)
|
589.22M
461.30M – 717.08M
+230.8% YoY
|
7.84B
3.92B – 11.76B
+1,230.2% YoY
|
18.00B
14.09B – 21.90B
+129.6% YoY
|
27.76B
21.73B – 33.78B
+54.2% YoY
|
48.45B
37.93B – 58.97B
+74.6% YoY
|
| EPS |
-2.99
est: -2.64 (-13.4%)
|
-2.15
est: -2.16 (+0.4%)
|
-3.62
est: -3.36 (-7.6%)
|
-5.12
est: -5.44 (+5.8%)
|
116.58
est: 111.60 (+4.5%)
|
-9.04
est: -9.01 (-0.3%)
|
-9.24
-11.84 – -6.63
-2.5% YoY
|
-6.53
-8.37 – -4.69
+29.3% YoY
|
-3.98
-6.74 – -1.21
+39.1% YoY
|
-2.73
-3.50 – -1.96
+31.3% YoY
|
2.76
1.98 – 3.54
+201.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-09 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-08 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-05 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-04 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-03 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-02 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-01 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-132.55M
OE per share TTM
-8.55
Owner's Yield
-9.55%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
205.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
47
Total invested
201.63M
Insider transactions (90d)
5
Beneficial owners (>5%)
37
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | C. Ott | 5.31M | 14.10% | — | 5.31M | — | — | IN | United States | 2021-02-16 | ↗ |
| 2 | S. Shabet | 5.31M | 14.10% | — | 5.31M | — | — | IN | United States | 2021-02-16 | ↗ |
| 3 | 50 LLC | 3.88M | 10.30% | — | 3.88M | — | — | OO | Delaware | 2021-02-16 | ↗ |
| 4 | Jon F. Kayyem and Paige Gates-Kayyem Family Trust | 3.40M | 9.00% | — | 3.40M | — | 3.40M | OO | Citizenship or Place of Organization United States | 2021-02-12 | ↗ |
| 5 | Peter Kolchinsky | 3.19M | 8.16% | — | 3.19M | — | — | HC, IN | Delaware | 2022-10-17 | ↗ |
| 6 | RA Capital Healthcare Fund, L.P. | 3.19M | 8.16% | — | 3.19M | — | — | PN | Delaware | 2022-10-17 | ↗ |
| 7 | RA Capital Management, L.P. | 3.19M | 8.16% | — | 3.19M | — | — | IA, PN | Delaware | 2022-10-17 | ↗ |
| 8 | Rajeev Shah | 3.19M | 8.16% | — | 3.19M | — | — | HC, IN | Delaware | 2022-10-17 | ↗ |
| 9 | Mark P. Lappe | 3.15M | 8.40% | 59.5K | 3.09M | 59.5K | 3.15M | IN | Citizenship or Place of Organization United States | 2021-02-12 | ↗ |
| 10 | Brendan P. Eckelman | 2.75M | 7.30% | — | 2.75M | — | 2.75M | IN | Citizenship or Place of Organization United States | 2021-02-12 | ↗ |
| 11 | Quinn L. Deveraux | 2.75M | 7.30% | 2.75M | — | 2.75M | 2.75M | IN | United States | 2021-02-12 | ↗ |
| 12 | Lappe Family Trust | 2.59M | 6.90% | — | 2.59M | — | 2.59M | OO | United States | 2021-02-12 | ↗ |
| 13 | Eckelman Living Trust Dated February 5, 2014 | 2.59M | 6.90% | — | 2.59M | — | 2.59M | OO | United States | 2021-02-12 | ↗ |
| 14 | STATE STREET CORPORATION | 2.51M | 5.76% | — | — | — | — | HC | — | 2023-02-08 | ↗ |
| 15 | (1) BlackRock, Inc. | 2.42M | 5.50% | 2.38M | — | 2.42M | — | HC | Delaware | 2023-02-03 | ↗ |
| 16 | Advisors LLC | 1.97M | 5.00% | — | 1.97M | — | 1.97M | IA | United States of America | 2022-07-19 | ↗ |
| 17 | Edelman | 1.97M | 5.00% | — | 1.97M | — | 1.97M | IN | United States of America | 2022-07-19 | ↗ |
| 18 | Sciences Master Fund, Ltd. | 1.97M | 5.00% | — | 1.97M | — | 1.97M | CO | United States of America | 2022-07-19 | ↗ |
| 19 | David C. Ott | 1.79M | 12.30% | — | 1.79M | — | 1.79M | IN | Delaware | 2024-06-07 | ↗ |
| 20 | O. Andreas Halvorsen | 1.79M | 12.30% | — | 1.79M | — | 1.79M | IN | Delaware | 2024-06-07 | ↗ |
| 21 | Rose S. Shabet | 1.79M | 12.30% | — | 1.79M | — | 1.79M | IN | Delaware | 2024-06-07 | ↗ |
| 22 | Viking Global Investors LP | 1.79M | 12.30% | — | 1.79M | — | 1.79M | PN | Delaware | 2024-06-07 | ↗ |
| 23 | Viking Global Opportunities Parent GP LLC | 1.79M | 12.30% | — | 1.79M | — | 1.79M | OO | Delaware | 2024-06-07 | ↗ |
| 24 | Viking Global Opportunities GP LLC | 1.66M | 11.50% | — | 1.66M | — | 1.66M | OO | Delaware | 2024-06-07 | ↗ |
| 25 | Viking Global Opportunities Illiquid Investments Sub-Master LP | 1.58M | 10.90% | — | 1.58M | — | 1.58M | PN | Delaware | 2024-06-07 | ↗ |
| 26 | Viking Global Opportunities Portfolio GP LLC | 1.58M | 10.90% | — | 1.58M | — | 1.58M | OO | Delaware | 2024-06-07 | ↗ |
| 27 | Joseph Edelman | 1.49M | 9.90% | — | 1.49M | — | 1.49M | IN | Delaware | 2024-11-14 | ↗ |
| 28 | Perceptive Life Sciences Master Fund, Ltd. | 1.49M | 9.90% | — | 1.49M | — | 1.49M | CO | Delaware | 2024-11-14 | ↗ |
| 29 | Perceptive Advisors LLC | 1.46M | 9.99% | 1.46M | 1.46M | 1.46M | — | IA | DELAWARE | 2026-05-15 | ↗ |
| 30 | Sanofi | 1.16M | 8.00% | 1.16M | — | 1.16M | — | CO | The Republic of France | 2024-05-31 | ↗ |
| 31 | Morgan Stanley | 1.16M | 7.90% | 1.16M | 1.16M | 1.16M | — | HC, CO | DELAWARE | 2026-02-11 | ↗ |
| 32 | Jon Faiz Kayyem | 1.15M | 7.90% | — | 1.15M | — | 1.15M | IN | UNITED STATES | 2025-02-26 | ↗ |
| 33 | Mark Lappe | 925.4K | 6.40% | 54.9K | 870.5K | 54.9K | 870.5K | IN | UNITED STATES | 2025-02-26 | ↗ |
| 34 | Viking Global Opportunities Drawdown (Aggregator) LP | 127.9K | 0.90% | — | 127.9K | — | 127.9K | PN | Delaware | 2024-06-07 | ↗ |
| 35 | Viking Global Opportunities Drawdown GP LLC | 127.9K | 0.90% | — | 127.9K | — | 127.9K | OO | Delaware | 2024-06-07 | ↗ |
| 36 | Viking Global Opportunities Drawdown Portfolio GP LLC | 127.9K | 0.90% | — | 127.9K | — | 127.9K | OO | Delaware | 2024-06-07 | ↗ |
| 37 | KAVRA 104 LLC | 83.3K | 0.60% | — | 83.3K | — | 83.3K | OO | Delaware | 2024-06-07 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
47
-108 vs prev Q
New positions
10
Closed positions
104
Increased
25
Reduced
8
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | PERCEPTIVE ADVISORS LLC | 1.45M +125.0K (+9.4%) | 114.76M +70.0M (+156.6%) | 9.39% +0.802 pp | 2.05% +0.754 pp | USD24.16 +227.0% | 7 qtrs — |
| 2 | VIKING GLOBAL INVESTORS LP | 1.44M -350.0K (-19.6%) | 113.58M +53.4M (+88.6%) | 9.29% -2.269 pp | 0.30% +0.145 pp | USD13.74 +475.0% | 7 qtrs — |
| 3 | MORGAN STANLEY | 1.17M +724.9K (+163.7%) | 92.25M +77.3M (+518.5%) | 7.54% +4.681 pp | 0.01% +0.005 pp | USD61.34 +28.8% | 7 qtrs — |
| 4 | SANOFI | 1.16M +— (+0.0%) | 91.48M +52.5M (+134.6%) | 7.48% -0.005 pp | 29.47% +14.490 pp | USD15.40 +413.0% | 5 qtrs — |
| 5 | HIGHTOWER ADVISORS, LLC | 870.5K -1.3K (-0.1%) | 68.77M +39.4M (+134.2%) | 5.62% -0.012 pp | 0.08% +0.042 pp | USD15.05 +424.9% | 7 qtrs — |
| 6 | BLACKROCK, INC. | 777.4K +92.6K (+13.5%) | 61.41M +38.4M (+166.3%) | 5.02% +0.596 pp | 0.00% +0.001 pp | USD23.17 +241.0% | 6 qtrs — |
| 7 | VANGUARD GROUP INC | 623.1K +28.2K (+4.7%) | 49.22M +29.2M (+145.7%) | 4.03% +0.180 pp | 0.00% +0.000 pp | USD17.05 +363.3% | 7 qtrs — |
| 8 | SOFINNOVA INVESTMENTS, INC. | 454.7K +14.6K (+3.3%) | 35.92M +21.1M (+142.3%) | 2.94% +0.092 pp | 1.55% +0.738 pp | USD16.08 +391.3% | 7 qtrs — |
| 9 | CAPITAL RESEARCH GLOBAL INVESTORS | 421.6K +421.6K (+100.0%) | 33.30M +33.3M (+100.0%) | 2.72% +2.724 pp | 0.01% +0.006 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 10 | STATE STREET CORP | 375.0K +171.0K (+83.9%) | 29.62M +22.8M (+331.3%) | 2.42% +1.104 pp | 0.00% +0.001 pp | USD43.68 +80.9% | 7 qtrs — |
| 11 | CALIGAN PARTNERS LP | 323.6K +87.2K (+36.9%) | 25.56M +17.6M (+221.1%) | 2.09% +0.562 pp | 2.10% +1.062 pp | USD45.89 +72.2% | 2 qtrs — |
| 12 | MILLENNIUM MANAGEMENT LLC | 275.9K -21.9K (-7.4%) | 21.80M +11.8M (+117.3%) | 1.78% -0.143 pp | 0.01% +0.005 pp | USD15.25 +418.0% | 7 qtrs — |
| 13 | PFM HEALTH SCIENCES, LP | 265.5K +25.9K (+10.8%) | 20.98M +12.9M (+159.9%) | 1.72% +0.166 pp | 2.09% +1.471 pp | USD20.26 +289.9% | 7 qtrs — |
| 14 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 264.0K +264.0K (+100.0%) | 20.86M +20.9M (+100.0%) | 1.71% +1.706 pp | 0.03% +0.035 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 226.0K +4.1K (+1.8%) | 17.86M +10.4M (+138.9%) | 1.46% +0.026 pp | 0.00% +0.001 pp | USD15.25 +418.0% | 7 qtrs — |
| 16 | SCHONFELD STRATEGIC ADVISORS LLC | 214.7K +117.3K (+120.5%) | 16.96M +13.7M (+417.2%) | 1.39% +0.758 pp | 0.08% +0.057 pp | USD49.80 +58.6% | 7 qtrs — |
| 17 | WOODLINE PARTNERS LP | 139.5K -197.1K (-58.6%) | 11.02M -317.5K (-2.8%) | 0.90% -1.275 pp | 0.04% -0.011 pp | USD14.12 +459.5% | 4 qtrs — |
| 18 | NORGES BANK | 133.3K +133.3K (+100.0%) | 10.53M +10.5M (+100.0%) | 0.86% +0.861 pp | 0.00% +0.001 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 19 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 125.1K +104.5K (+507.3%) | 9.88M +9.2M (+1,324.4%) | 0.81% +0.675 pp | 0.00% +0.001 pp | USD71.54 +10.4% | 7 qtrs — |
| 20 | D. E. SHAW & CO., INC. | 122.1K +110.5K (+956.9%) | 9.65M +9.3M (+2,379.0%) | 0.79% +0.714 pp | 0.01% +0.005 pp | USD74.71 +5.7% | 2 qtrs — |
| 21 | INVESCO LTD. | 112.4K +94.8K (+539.6%) | 8.88M +8.3M (+1,400.2%) | 0.73% +0.613 pp | 0.00% +0.001 pp | USD69.58 +13.5% | 3 qtrs — |
| 22 | — | 110.8K +110.8K (+100.0%) | 8.75M +8.8M (+100.0%) | 0.72% +0.716 pp | 4.10% +4.098 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 23 | GOLDMAN SACHS GROUP INC | 100.6K +74.7K (+287.5%) | 7.95M +7.1M (+808.9%) | 0.65% +0.482 pp | 0.00% +0.001 pp | USD65.30 +21.0% | 6 qtrs — |
| 24 | BOOTHBAY FUND MANAGEMENT, LLC | 92.0K +13.2K (+16.7%) | 7.27M +4.6M (+173.8%) | 0.59% +0.085 pp | 0.11% +0.070 pp | USD34.06 +131.9% | 7 qtrs — |
| 25 | NORTHERN TRUST CORP | 88.5K -4.1K (-4.5%) | 6.99M +3.9M (+124.1%) | 0.57% -0.027 pp | 0.00% +0.001 pp | USD14.43 +447.5% | 7 qtrs — |
| 26 | SUMMITTX CAPITAL, L.P. | 82.9K +28.7K (+53.1%) | 6.55M +4.7M (+259.1%) | 0.54% +0.186 pp | 0.20% +0.122 pp | USD49.40 +59.9% | 2 qtrs — |
| 27 | UBS GROUP AG | 73.7K +64.3K (+681.9%) | 5.82M +5.5M (+1,734.0%) | 0.48% +0.415 pp | 0.00% +0.001 pp | USD70.76 +11.6% | 7 qtrs — |
| 28 | KENNEDY CAPITAL MANAGEMENT LLC | 71.5K -90.4K (-55.8%) | 5.65M +194.5K (+3.6%) | 0.46% -0.585 pp | 0.12% -0.001 pp | USD13.79 +472.9% | 7 qtrs — |
| 29 | BANK OF AMERICA CORP /DE/ | 69.1K +51.3K (+287.6%) | 5.46M +4.9M (+809.2%) | 0.45% +0.331 pp | 0.00% +0.000 pp | USD64.72 +22.1% | 7 qtrs — |
| 30 | DLD ASSET MANAGEMENT, LP | 61.1K +61.1K (+100.0%) | 4.83M +4.8M (+100.0%) | 0.39% +0.395 pp | 0.36% +0.357 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 31 | CITIGROUP INC | 55.8K +50.8K (+1,021.7%) | 4.40M +4.2M (+2,531.0%) | 0.36% +0.328 pp | 0.00% +0.002 pp | USD73.83 +7.0% | 7 qtrs — |
| 32 | JANE STREET GROUP, LLC | 52.9K +52.9K (+100.0%) | 4.18M +4.2M (+100.0%) | 0.34% +0.342 pp | 0.00% +0.001 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 33 | RENAISSANCE TECHNOLOGIES LLC | 52.6K +44.2K (+526.2%) | 4.16M +3.9M (+1,368.8%) | 0.34% +0.286 pp | 0.01% +0.006 pp | USD71.76 +10.1% | 2 qtrs — |
| 34 | FMR LLC | 46.3K +6.9K (+17.7%) | 3.66M +2.3M (+176.0%) | 0.30% +0.045 pp | 0.00% +0.000 pp | USD24.06 +228.3% | 7 qtrs — |
| 35 | CITADEL ADVISORS LLC | 43.8K +43.8K (+100.0%) | 3.46M +3.5M (+100.0%) | 0.28% +0.283 pp | 0.00% +0.001 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 36 | LAIRD NORTON TRUST COMPANY, LLC | 40.4K +40.4K (+100.0%) | 3.19M +3.2M (+100.0%) | 0.26% +0.261 pp | 0.07% +0.066 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 37 | ARROWMARK COLORADO HOLDINGS LLC | 35.2K +— (+0.0%) | 2.78M +1.6M (+134.6%) | 0.23% 0.000 pp | 0.06% +0.039 pp | USD13.84 +470.8% | 7 qtrs — |
| 38 | CAPTION MANAGEMENT, LLC | 31.6K +31.6K (+100.0%) | 2.50M +2.5M (+100.0%) | 0.20% +0.204 pp | 0.02% +0.017 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 39 | MARSHALL WACE, LLP | 29.3K +2.1K (+7.6%) | 2.32M +1.4M (+152.4%) | 0.19% +0.013 pp | 0.00% +0.001 pp | USD36.88 +114.2% | 2 qtrs — |
| 40 | FRANKLIN RESOURCES INC | 29.3K +12.1K (+70.8%) | 2.32M +1.7M (+300.5%) | 0.19% +0.078 pp | 0.00% +0.000 pp | USD41.09 +92.3% | 3 qtrs — |
| 41 | WELLINGTON MANAGEMENT GROUP LLP | 28.4K -1.4K (-4.6%) | 2.24M +1.2M (+123.8%) | 0.18% -0.009 pp | 0.00% +0.000 pp | USD33.68 +134.6% | 2 qtrs — |
| 42 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 27.3K -452.0 (-1.6%) | 2.16M +1.2M (+130.7%) | 0.18% -0.003 pp | 0.00% +0.000 pp | USD14.09 +460.7% | 7 qtrs — |
| 43 | BANK OF NEW YORK MELLON CORP | 26.7K -23.4K (-46.6%) | 2.11M +424.9K (+25.2%) | 0.17% -0.151 pp | 0.00% +0.000 pp | USD14.55 +443.0% | 7 qtrs — |
| 44 | ACADIAN ASSET MANAGEMENT LLC | 25.4K -3.1K (-10.7%) | 2.01M +1.0M (+109.5%) | 0.16% -0.020 pp | 0.00% +0.002 pp | USD15.11 +422.8% | 6 qtrs — |
| 45 | SOLEUS CAPITAL MANAGEMENT, L.P. | 25.0K +25.0K (+100.0%) | 1.98M +2.0M (+100.0%) | 0.16% +0.162 pp | 0.07% +0.073 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 46 | EMPIRICAL FINANCIAL SERVICES, LLC D.B.A. EMPIRICAL WEALTH MANAGEMENT | 22.9K +299.0 (+1.3%) | 1.81M +1.0M (+137.7%) | 0.15% +0.002 pp | 0.03% +0.017 pp | USD16.23 +386.8% | 5 qtrs — |
| 47 | BARCLAYS PLC | 21.9K +5.8K (+36.3%) | 1.73M +1.5M (+587.5%) | 0.14% +0.038 pp | 0.00% +0.000 pp | USD32.06 +146.4% | 7 qtrs — |
| 48 | RUSSELL INVESTMENTS GROUP, LTD. | 20.8K -17.4K (-45.5%) | 1.64M +357.1K (+27.8%) | 0.13% -0.112 pp | 0.00% +0.000 pp | USD18.26 +332.6% | 7 qtrs — |
| 49 | CI PRIVATE WEALTH, LLC | 20.4K +20.4K (+100.0%) | 1.61M +1.6M (+100.0%) | 0.13% +0.132 pp | 0.00% +0.002 pp | USD79.00 +0.0% | 6 qtrs — |
| 50 | NUVEEN, LLC | 17.1K -494.0 (-2.8%) | 1.35M +757.9K (+128.0%) | 0.11% -0.003 pp | 0.00% +0.000 pp | USD13.99 +464.7% | 4 qtrs — |
| 51 | JPMORGAN CHASE & CO | 17.1K +12.2K (+253.3%) | 1.35M +1.2M (+728.6%) | 0.11% +0.079 pp | 0.00% +0.000 pp | USD60.68 +30.2% | 7 qtrs — |
| 52 | ACUTA CAPITAL PARTNERS, LLC | 16.4K +— (+0.0%) | 1.29M +742.2K (+134.6%) | 0.11% 0.000 pp | 0.88% +0.308 pp | USD33.68 +134.6% | 2 qtrs — |
| 53 | SG AMERICAS SECURITIES, LLC | 16.1K +16.1K (+100.0%) | 1.27M +1.3M (+100.0%) | 0.10% +0.104 pp | 0.00% +0.002 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 54 | GROUPE LA FRANCAISE | 15.6K -31.7K (-67.0%) | 1.24M -359.0K (-22.5%) | 0.10% -0.205 pp | 0.02% -0.004 pp | USD13.99 +464.7% | 4 qtrs — |
| 55 | NOMURA HOLDINGS INC | 15.5K +15.5K (+100.0%) | 1.22M +1.2M (+100.0%) | 0.10% +0.100 pp | 0.00% +0.002 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 56 | VOLEON CAPITAL MANAGEMENT LP | 15.0K +15.0K (+100.0%) | 1.19M +1.2M (+100.0%) | 0.10% +0.097 pp | 0.03% +0.026 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 57 | BNP PARIBAS ARBITRAGE, SNC | 14.9K +13.0K (+687.4%) | 1.17M +1.1M (+1,746.9%) | 0.10% +0.084 pp | 0.00% +0.001 pp | USD71.87 +9.9% | 7 qtrs — |
| 58 | ETHIC INC. | 13.0K -1.5K (-10.5%) | 1.02M +536.8K (+110.0%) | 0.08% -0.010 pp | 0.02% +0.008 pp | USD14.27 +453.6% | 3 qtrs — |
| 59 | MARINER, LLC | 12.7K -4.6K (-26.5%) | 1.01M +423.7K (+72.5%) | 0.08% -0.030 pp | 0.00% +0.000 pp | USD20.11 +292.8% | 4 qtrs — |
| 60 | JAIN GLOBAL LLC | 12.1K +12.1K (+100.0%) | 955.7K +955.7K (+100.0%) | 0.08% +0.078 pp | 0.00% +0.005 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 61 | VICTORY CAPITAL MANAGEMENT INC | 12.0K +12.0K (+100.0%) | 945.1K +945.1K (+100.0%) | 0.08% +0.077 pp | 0.00% +0.001 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 62 | RHUMBLINE ADVISERS | 11.4K -2.3K (-16.7%) | 903.4K +440.8K (+95.3%) | 0.07% -0.015 pp | 0.00% +0.000 pp | USD13.86 +470.0% | 7 qtrs — |
| 63 | WELLS FARGO & COMPANY/MN | 10.8K +3.2K (+42.3%) | 854.2K +598.3K (+233.8%) | 0.07% +0.021 pp | 0.00% +0.000 pp | USD35.55 +122.2% | 7 qtrs — |
| 64 | MERIDIAN WEALTH ADVISORS, LLC | 10.5K -14.5K (-58.0%) | 829.5K -12.5K (-1.5%) | 0.07% -0.094 pp | 0.11% -0.005 pp | USD15.40 +413.0% | 5 qtrs — |
| 65 | JACOBS LEVY EQUITY MANAGEMENT, INC | 10.1K -3.6K (-26.1%) | 801.1K +339.1K (+73.4%) | 0.07% -0.023 pp | 0.00% +0.001 pp | USD33.68 +134.6% | 2 qtrs — |
| 66 | QUANTINNO CAPITAL MANAGEMENT LP | 10.0K -1.8K (-15.1%) | 793.0K +394.7K (+99.1%) | 0.06% -0.012 pp | 0.00% +0.001 pp | USD33.68 +134.6% | 2 qtrs — |
| 67 | XTX TOPCO LTD | 9.0K +9.0K (+100.0%) | 712.7K +712.7K (+100.0%) | 0.06% +0.058 pp | 0.02% +0.019 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 68 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 9.0K -7.5K (-45.5%) | 711.0K +155.3K (+27.9%) | 0.06% -0.049 pp | 0.01% +0.003 pp | USD14.27 +453.6% | 3 qtrs — |
| 69 | ALLIANCEBERNSTEIN L.P. | 9.0K -10.3K (-53.5%) | 707.1K +59.4K (+9.2%) | 0.06% -0.067 pp | 0.00% +0.000 pp | USD13.80 +472.5% | 7 qtrs — |
| 70 | JEFFERIES FINANCIAL GROUP INC. | 8.9K +8.9K (+100.0%) | 703.2K +703.2K (+100.0%) | 0.06% +0.058 pp | 0.00% +0.004 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 71 | CREDIT INDUSTRIEL ET COMMERCIAL | 8.7K -20.3K (-70.1%) | 683.8K -291.5K (-29.9%) | 0.06% -0.131 pp | 0.05% -0.029 pp | USD15.40 +413.0% | 5 qtrs — |
| 72 | RAFFERTY ASSET MANAGEMENT, LLC | 8.6K +8.6K (+100.0%) | 678.0K +678.0K (+100.0%) | 0.06% +0.055 pp | 0.00% +0.002 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 73 | AQR CAPITAL MANAGEMENT LLC | 7.5K +1.5K (+25.1%) | 592.6K +390.6K (+193.3%) | 0.05% +0.010 pp | 0.00% +0.000 pp | USD42.76 +84.8% | 2 qtrs — |
| 74 | BELVEDERE TRADING LLC | 7.4K +1.1K (+17.9%) | 584.8K +373.3K (+176.6%) | 0.05% +0.007 pp | 0.00% +0.000 pp | USD40.57 +94.7% | 2 qtrs — |
| 75 | DEUTSCHE BANK AG\ | 6.6K +6.6K (+100.0%) | 524.4K +524.4K (+100.0%) | 0.04% +0.043 pp | 0.00% +0.000 pp | USD79.00 +0.0% | 7 qtrs — |
| 76 | CREATIVE PLANNING | 5.7K +5.7K (+100.0%) | 450.9K +450.9K (+100.0%) | 0.04% +0.037 pp | 0.00% +0.000 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 77 | VOYA INVESTMENT MANAGEMENT LLC | 5.6K +5.6K (+100.0%) | 439.6K +439.6K (+100.0%) | 0.04% +0.036 pp | 0.00% +0.000 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 78 | JANNEY MONTGOMERY SCOTT LLC | 5.5K +5.5K (+100.0%) | 434.0K +434.0K (+100.0%) | 0.04% +0.036 pp | 0.00% +0.001 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 79 | GROUP ONE TRADING, L.P. | 5.4K +5.4K (+100.0%) | 423.3K +423.3K (+100.0%) | 0.03% +0.035 pp | 0.00% +0.001 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 80 | PRICE T ROWE ASSOCIATES INC /MD/ | 5.3K +5.3K (+100.0%) | 422.0K +422.0K (+100.0%) | 0.03% +0.035 pp | 0.00% +0.000 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 81 | METLIFE INVESTMENT MANAGEMENT, LLC | 5.3K -2.1K (-28.4%) | 420.3K +170.2K (+68.1%) | 0.03% -0.014 pp | 0.00% +0.001 pp | USD14.39 +449.0% | 7 qtrs — |
| 82 | HARVEST INVESTMENT SERVICES, LLC | 5.0K +5.0K (+100.0%) | 398.9K +398.9K (+100.0%) | 0.03% +0.033 pp | 0.08% +0.075 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 83 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 4.7K +582.0 (+14.1%) | 371.7K +232.6K (+167.2%) | 0.03% +0.004 pp | 0.00% +0.000 pp | USD22.21 +255.7% | 7 qtrs — |
| 84 | TUDOR INVESTMENT CORP ET AL | 4.6K +4.6K (+100.0%) | 366.7K +366.7K (+100.0%) | 0.03% +0.030 pp | 0.00% +0.001 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 85 | SIG BROKERAGE, LP | 4.5K +4.5K (+100.0%) | 355.5K +355.5K (+100.0%) | 0.03% +0.029 pp | 0.01% +0.011 pp | USD79.00 +0.0% | 1 qtrs NEW |
| 86 | STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 3.8K +3.8K (+100.0%) | 300.2K +300.2K (+100.0%) | 0.02% +0.025 pp | 0.00% +0.001 pp | USD79.00 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 84 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.62% | 357.5K | 0.65% |
| 2 | Tema Oncology ETF CANC | 0.49% | 698.8K | 0.75% |
| 3 | Global X - S&P Biotech ETF CURE.AX | 0.35% | 124.5K | 0.45% |
| 4 | State Street SPDR S&P Biotech ETF XBI | 0.35% | 37.40M | 0.35% |
| 5 | First Trust Small Cap Core AlphaDEX Fund FYX | 0.25% | 3.41M | 0.58% |
| 6 | VictoryShares US Small Mid Cap Value Momentum ETF USVM | 0.14% | 2.37M | 0.29% |
| 7 | First Trust Active Factor Small Cap ETF AFSM | 0.14% | 153.1K | 0.75% |
| 8 | First Trust Multi Cap Growth AlphaDEX Fund FAD | 0.10% | 584.5K | 0.63% |
| 9 | Vanguard U.S. Momentum Factor ETF VFMO | 0.10% | 1.72M | 0.13% |
| 10 | Vanguard Global Momentum Factor ETF VMO.TO | 0.10% | 363.4K | 0.38% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
5
Sells
0
Shares acquired
110.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+110,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-03 | Vuori Kristiina MD | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 95.22 | 1.43M | 15,000 | D | ↗ |
| 2026-06-03 | MANHARD KIMBERLY | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 95.22 | 1.43M | 15,000 | D | ↗ |
| 2026-06-03 | Kayyem Jon Faiz | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 95.22 | 1.43M | 15,000 | D | ↗ |
| 2026-06-03 | FORSYTH DOUGLAS | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 95.22 | 1.43M | 15,000 | D | ↗ |
| 2026-04-24 | Matly David | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 129.06 | 6.45M | 50,000 | D | ↗ |
| 2025-10-07 | VIKING GLOBAL INVESTORS LP | 10% Owner | S-Sale | D | Common Stock | 308,643 | 32.25 | 9.95M | 1,267,823 | I | ↗ |
| 2025-05-28 | Vuori Kristiina MD | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 12.91 | 193.7K | 15,000 | D | ↗ |
| 2025-05-28 | MANHARD KIMBERLY | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 12.91 | 193.7K | 15,000 | D | ↗ |
| 2025-05-28 | Kayyem Jon Faiz | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 12.91 | 193.7K | 15,000 | D | ↗ |
| 2025-05-28 | FORSYTH DOUGLAS | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 12.91 | 193.7K | 15,000 | D | ↗ |
| 2025-04-01 | Matly David | Officer | — | — | Stock Option (right to buy) | 175,000 | 15.86 | 2.78M | 0 | D | ↗ |
| 2025-04-01 | Deck Kelly | Officer | A-Award | A | Stock Option (right to buy) | 15,000 | 14.05 | 210.8K | 15,000 | D | ↗ |
| 2025-03-27 | Kayyem Jon Faiz | Director | G-Gift | D | Common Stock | 90,000 | 0.00 | — | 419,360 | I | ↗ |
| 2024-12-16 | Kayyem Jon Faiz | Director | G-Gift | D | Common Stock | 500,000 | 0.00 | — | 509,360 | I | ↗ |
| 2024-12-06 | Kayyem Jon Faiz | Director | G-Gift | D | Common Stock | 52,000 | 0.00 | — | 1,009,360 | I | ↗ |
| 2024-11-20 | Kayyem Jon Faiz | Director | P-Purchase | A | Common Stock | 18,750 | 14.19 | 266.1K | 69,843 | I | ↗ |
| 2024-11-19 | Kayyem Jon Faiz | Director | P-Purchase | A | Common Stock | 34,843 | 14.23 | 495.7K | 51,093 | I | ↗ |
| 2024-10-03 | Vuori Kristiina MD | Director | P-Purchase | A | Common Stock | 6,667 | 15.00 | 100.0K | 20,443 | D | ↗ |
| 2024-09-16 | Lappe Mark | Director / Officer | P-Purchase | A | Common Stock | 13,037 | 17.13 | 223.3K | 705,548 | — | ↗ |
| 2024-09-12 | Lappe Mark | Director / Officer | P-Purchase | A | Common Stock | 26,963 | 15.05 | 405.8K | 692,511 | — | ↗ |
| 2024-09-11 | Vuori Kristiina MD | Director | P-Purchase | A | Common Stock | 6,457 | 15.07 | 97.3K | 13,776 | — | ↗ |
| 2024-09-10 | Vuori Kristiina MD | Director | P-Purchase | A | Common Stock | 179 | 15.00 | 2.7K | 7,319 | — | ↗ |
| 2024-09-10 | Lappe Mark | Director / Officer | P-Purchase | A | Common Stock | 8,500 | 15.19 | 129.1K | 665,548 | — | ↗ |
| 2024-09-09 | Lappe Mark | Director / Officer | P-Purchase | A | Common Stock | 9,500 | 15.21 | 144.5K | 657,048 | — | ↗ |
| 2024-09-06 | Lappe Mark | Director / Officer | P-Purchase | A | Common Stock | 26,000 | 15.29 | 397.5K | 647,548 | — | ↗ |
| 2024-05-30 | Vuori Kristiina MD | Director | D-Return | D | Stock Option (right to buy) | 15,000 | 23.03 | 345.5K | 0 | — | ↗ |
| 2024-05-30 | VIKING GLOBAL INVESTORS LP | 10% Owner | J-Other | D | Common Stock | 511,627 | 30.00 | 15.35M | 0 | — | ↗ |
| 2024-05-30 | MANHARD KIMBERLY | Director | D-Return | D | Stock Option (right to buy) | 3,500 | 17.44 | 61.0K | 0 | — | ↗ |
| 2024-05-30 | Lappe Mark | Director / Officer | D-Return | D | Stock Option (right to buy) | 145,000 | 33.63 | 4.88M | 0 | — | ↗ |
| 2024-05-30 | Kayyem Jon Faiz | Director | D-Return | D | Stock Option (right to buy) | 15,000 | 12.57 | 188.6K | 0 | — | ↗ |
| 2024-05-30 | FORSYTH DOUGLAS | Director | D-Return | D | Stock Option (right to buy) | 15,000 | 24.78 | 371.7K | 0 | — | ↗ |
| 2024-05-30 | Eckelman Brendan P. | Officer | D-Return | D | Stock Option (right to buy) | 26,667 | 23.30 | 621.3K | 0 | — | ↗ |
| 2024-05-30 | Deck Kelly | Officer | D-Return | D | Stock Option (right to buy) | 21,250 | 23.30 | 495.1K | 0 | — | ↗ |
| 2024-05-29 | Inhibrx, Inc. | 10% Owner | J-Other | D | Common Stock, par value $0.0001 per share | 13,316,140 | 0.00 | — | 1,157,926 | — | ↗ |
| 2024-05-28 | Eckelman Brendan P. | Officer | S-Sale | D | Common Stock | 300,000 | 34.30 | 10.29M | 1,735,553 | — | ↗ |
| 2024-05-22 | Eckelman Brendan P. | Officer | M-Exempt | D | Stock Option (right to buy) | 2,510 | 33.63 | 84.4K | 6,667 | — | ↗ |
| 2024-05-06 | Deck Kelly | Officer | M-Exempt | D | Stock Option (right to buy) | 17,624 | 10.52 | 185.4K | 0 | — | ↗ |
| 2024-03-26 | Deck Kelly | Officer | M-Exempt | D | Stock Option (right to buy) | 625 | 23.30 | 14.6K | 21,250 | — | ↗ |
| 2024-03-22 | Deck Kelly | Officer | M-Exempt | D | Stock Option (right to buy) | 110 | 10.52 | 1.2K | 18,020 | — | ↗ |
| 2024-03-21 | Deck Kelly | Officer | M-Exempt | D | Stock Option (right to buy) | 3,113 | 10.52 | 32.7K | 18,130 | — | ↗ |
| 2024-03-20 | Deck Kelly | Officer | M-Exempt | D | Stock Option (right to buy) | 16,777 | 10.52 | 176.5K | 21,243 | — | ↗ |
| 2024-03-13 | Eckelman Brendan P. | Officer | M-Exempt | D | Stock Option (right to buy) | 1,898 | 33.63 | 63.8K | 9,177 | — | ↗ |
| 2024-03-13 | Deck Kelly | Officer | M-Exempt | D | Stock Option (right to buy) | 32,431 | 11.25 | 364.8K | 2,087 | — | ↗ |
| 2024-03-12 | Eckelman Brendan P. | Officer | M-Exempt | D | Stock Option (right to buy) | 4,152 | 23.30 | 96.7K | 29,167 | — | ↗ |
| 2024-03-11 | Eckelman Brendan P. | Officer | M-Exempt | D | Stock Option (right to buy) | 6,681 | 23.30 | 155.7K | 33,319 | — | ↗ |
| 2024-03-08 | Eckelman Brendan P. | Officer | M-Exempt | D | Stock Option (right to buy) | 2,150 | 33.63 | 72.3K | 37,850 | — | ↗ |
| 2024-03-08 | Deck Kelly | Officer | M-Exempt | D | Stock Option (right to buy) | 42,523 | 10.52 | 447.3K | 38,020 | — | ↗ |
| 2024-03-05 | Deck Kelly | Officer | M-Exempt | D | Stock Option (right to buy) | 10,417 | 34.16 | 355.8K | 9,583 | — | ↗ |
| 2024-03-04 | Deck Kelly | Officer | M-Exempt | D | Stock Option (right to buy) | 8,125 | 23.30 | 189.3K | 21,875 | — | ↗ |
| 2023-08-28 | VIKING GLOBAL INVESTORS LP | 10% Owner | P-Purchase | A | Warrants (right to buy) | 1,038,765 | 0.00 | 103.88 | 1,038,765 | — | ↗ |
| 2023-05-25 | Vuori Kristiina MD | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 23.03 | 345.5K | 15,000 | — | ↗ |
| 2023-05-25 | MANHARD KIMBERLY | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 23.03 | 345.5K | 15,000 | — | ↗ |
| 2023-05-25 | Kayyem Jon Faiz | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 23.03 | 345.5K | 15,000 | — | ↗ |
| 2023-05-25 | FORSYTH DOUGLAS | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 23.03 | 345.5K | 15,000 | — | ↗ |
| 2023-03-01 | Eckelman Brendan P. | Officer | S-Sale | D | Common Stock | 39,600 | 24.20 | 958.3K | 2,035,953 | — | ↗ |
| 2023-02-28 | Lappe Mark | Director / Officer | S-Sale | D | Common Stock | 60 | 25.02 | 1.5K | 2,486,192 | — | ↗ |
| 2023-02-02 | Eckelman Brendan P. | Officer | S-Sale | D | Common Stock | 10,120 | 25.40 | 257.1K | 2,076,683 | — | ↗ |
| 2023-02-01 | Eckelman Brendan P. | Officer | S-Sale | D | Common Stock | 14,608 | 25.08 | 366.4K | 2,087,496 | — | ↗ |
| 2023-01-24 | Lappe Mark | Officer | S-Sale | D | Common Stock | 4,272 | 25.71 | 109.8K | 2,486,315 | — | ↗ |
| 2023-01-23 | Lappe Mark | Officer | S-Sale | D | Common Stock | 21,665 | 25.36 | 549.4K | 2,490,587 | — | ↗ |
| 2023-01-23 | Kayyem Jon Faiz | Director | S-Sale | D | Common Stock | 9,500 | 25.26 | 240.0K | 3,224,301 | — | ↗ |
| 2023-01-04 | Eckelman Brendan P. | Officer | S-Sale | D | Common Stock | 4,102 | 23.11 | 94.8K | 2,118,556 | — | ↗ |
| 2023-01-03 | Lappe Mark | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2023-01-03 | Eckelman Brendan P. | Officer | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2023-01-03 | Deck Kelly | Officer | A-Award | A | Stock Option (right to buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-12-21 | Kayyem Jon Faiz | Director | S-Sale | D | Common Stock | 7,541 | 26.87 | 202.6K | 3,235,760 | — | ↗ |
| 2022-12-19 | Lappe Mark | Officer | S-Sale | D | Common Stock | 25,246 | 25.53 | 644.6K | 2,513,006 | — | ↗ |
| 2022-12-06 | Eckelman Brendan P. | Officer | S-Sale | D | Common Stock | 20,927 | 26.83 | 561.6K | 2,174,626 | — | ↗ |
| 2022-11-21 | Kayyem Jon Faiz | Director | S-Sale | D | Common Stock | 2,733 | 29.33 | 80.2K | 3,250,068 | — | ↗ |
| 2022-11-17 | Lappe Mark | Officer | S-Sale | D | Common Stock | 1,767 | 28.86 | 51.0K | 2,547,087 | — | ↗ |
| 2022-11-01 | Eckelman Brendan P. | Officer | S-Sale | D | Common Stock | 12,349 | 33.90 | 418.6K | 2,195,553 | — | ↗ |
| 2022-10-21 | Kayyem Jon Faiz | Director | S-Sale | D | Common Stock | 3,572 | 29.39 | 105.0K | 3,258,729 | — | ↗ |
| 2022-10-17 | Lappe Mark | Officer | S-Sale | D | Common Stock | 8,981 | 28.66 | 257.4K | 2,581,271 | — | ↗ |
| 2022-10-07 | Shabet Rose Sharon | Director | P-Purchase | A | Common Stock | 333,333 | 30.00 | 10.00M | 333,333 | — | ↗ |
| 2022-10-04 | Eckelman Living Trust Dated February 5, 2014 | Director | S-Sale | D | Common Stock | 100 | 30.52 | 3.1K | 2,235,553 | — | ↗ |
| 2022-10-04 | Eckelman Brendan P. | Officer | S-Sale | D | Common Stock | 100 | 30.52 | 3.1K | 2,235,553 | — | ↗ |
| 2022-09-13 | Eckelman Brendan P. | Officer | G-Gift | D | Common Stock | 160,000 | 0.00 | — | 2,275,553 | — | ↗ |
| 2022-09-06 | Eckelman Living Trust Dated February 5, 2014 | Director | S-Sale | D | Common Stock | 2,493 | 15.66 | 39.0K | 2,435,553 | — | ↗ |
| 2022-09-06 | Eckelman Brendan P. | Officer | S-Sale | D | Common Stock | 37,507 | 14.86 | 557.2K | 2,438,046 | — | ↗ |
| 2022-08-24 | Kayyem Jon Faiz | Director | G-Gift | D | Common Stock | 11,900 | 0.00 | — | 3,262,301 | — | ↗ |
| 2022-08-05 | Kayyem Jon Faiz | Director | G-Gift | D | Common Stock | 3,400 | 0.00 | — | 3,274,201 | — | ↗ |
| 2022-08-03 | Eckelman Brendan P. | Officer | S-Sale | D | Common Stock | 15,500 | 18.47 | 286.2K | 2,475,553 | — | ↗ |
| 2022-08-02 | Kayyem Jon Faiz | Director | G-Gift | A | Common Stock | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-08-02 | Eckelman Living Trust Dated February 5, 2014 | Director | S-Sale | D | Common Stock | 24,500 | 17.70 | 433.6K | 2,491,053 | — | ↗ |
| 2022-08-02 | Eckelman Brendan P. | Officer | S-Sale | D | Common Stock | 24,500 | 17.70 | 433.6K | 2,491,053 | — | ↗ |
| 2022-07-07 | Eckelman Living Trust Dated February 5, 2014 | Director | S-Sale | D | Common Stock | 40,000 | 17.17 | 686.8K | 2,515,553 | — | ↗ |
| 2022-07-07 | Eckelman Brendan P. | Officer | S-Sale | D | Common Stock | 40,000 | 17.17 | 686.8K | 2,515,553 | — | ↗ |
| 2022-05-25 | Vuori Kristiina MD | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 12.57 | 188.6K | 45,000 | — | ↗ |
| 2022-05-25 | MANHARD KIMBERLY | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 0.00 | — | 50,759 | — | ↗ |
| 2022-05-25 | Kayyem Jon Faiz | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 0.00 | — | 47,259 | — | ↗ |
| 2022-05-25 | FORSYTH DOUGLAS | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 0.00 | — | 47,259 | — | ↗ |
| 2022-04-05 | Eckelman Living Trust Dated February 5, 2014 | Director | S-Sale | D | Common Stock | 400 | 25.04 | 10.0K | 2,555,553 | — | ↗ |
| 2022-04-05 | Eckelman Brendan P. | Officer | S-Sale | D | Common Stock | 400 | 25.04 | 10.0K | 2,555,553 | — | ↗ |
| 2022-01-11 | Deck Kelly | Officer | A-Award | A | Stock Option (right to buy) | 20,000 | 34.16 | 683.2K | 20,000 | — | ↗ |
| 2021-12-07 | Vuori Kristiina MD | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 40.45 | 1.21M | 30,000 | — | ↗ |
| 2021-10-28 | Vuori Kristiina MD | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-07 | MANHARD KIMBERLY | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 24.78 | 371.7K | 35,759 | — | ↗ |
| 2021-06-07 | Kayyem Jon Faiz | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 24.78 | 371.7K | 32,259 | — | ↗ |
| 2021-06-07 | FORSYTH DOUGLAS | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 24.78 | 371.7K | 32,259 | — | ↗ |
| 2021-03-24 | Eckelman Brendan P. | Director / Officer | S-Sale | D | Common Stock | 17,000 | 19.02 | 323.3K | 2,555,953 | — | ↗ |
| 2021-02-17 | Wagner Klaus W. | Officer | S-Sale | D | Common Stock | 19,559 | 25.29 | 494.6K | 215,150 | — | ↗ |
| 2021-02-16 | Wagner Klaus W. | Officer | S-Sale | D | Common Stock | 156,474 | 24.32 | 3.81M | 234,709 | — | ↗ |
| 2021-02-16 | Eckelman Brendan P. | Director / Officer | S-Sale | D | Common Stock | 17,000 | 25.90 | 440.3K | 2,572,953 | — | ↗ |
| 2021-01-15 | Wagner Klaus W. | Officer | A-Award | A | Stock Option (right to buy) | 120,000 | 33.63 | 4.04M | 120,000 | — | ↗ |
| 2021-01-15 | Lappe Mark | Director / Officer | A-Award | A | Stock Option (right to buy) | 145,000 | 33.63 | 4.88M | 145,000 | — | ↗ |
| 2021-01-15 | Eckelman Brendan P. | Director / Officer | A-Award | A | Stock Option (right to buy) | 40,000 | 33.63 | 1.35M | 40,000 | — | ↗ |
| 2021-01-15 | Deck Kelly | Officer | A-Award | A | Stock Option (right to buy) | 70,000 | 33.63 | 2.35M | 70,000 | — | ↗ |
| 2020-12-28 | Lappe Mark | Director / Officer | G-Gift | A | Common Stock | 500,000 | 0.00 | — | 500,000 | — | ↗ |
| 2020-12-04 | Eckelman Brendan P. | Director / Officer | G-Gift | A | Common Stock | 80,000 | 0.00 | — | 80,000 | — | ↗ |
| 2020-08-26 | VIKING GLOBAL INVESTORS LP | 10% Owner | P-Purchase | A | Common Stock | 100,000 | 18.99 | 1.90M | 1,427,307 | — | ↗ |
| 2020-08-25 | VIKING GLOBAL INVESTORS LP | 10% Owner | P-Purchase | A | Common Stock | 70,479 | 19.39 | 1.37M | 1,247,088 | — | ↗ |
| 2020-08-24 | VIKING GLOBAL INVESTORS LP | 10% Owner | P-Purchase | A | Common Stock | 46,161 | 19.43 | 897.0K | 1,161,784 | — | ↗ |
| 2020-08-21 | VIKING GLOBAL INVESTORS LP | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,115,623 | — | ↗ |
| 2020-08-21 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | C-Conversion | D | Series Mezzanine 2 Preferred Stock | 3,700,634 | 0.00 | — | 0 | — | ↗ |
| 2020-08-21 | MANHARD KIMBERLY | Director | A-Award | A | Common Stock | 17,259 | 17.00 | 293.4K | 17,259 | — | ↗ |
| 2020-08-21 | FORSYTH DOUGLAS | Director | C-Conversion | D | Series Mezzanine 2 Preferred Stock | 143,266 | 0.00 | — | 0 | — | ↗ |
| 2020-08-18 | Wagner Klaus W. | Officer | — | D | Stock Option (right to buy) | 69,036 | 10.52 | 726.3K | 0 | — | ↗ |
| 2020-08-18 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | — | I | Series Mezzanine 2 Preferred Stock | 2,129,003 | 0.00 | — | 0 | — | ↗ |
| 2020-08-18 | MANHARD KIMBERLY | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-08-18 | Lappe Mark | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 59,462 | — | ↗ |
| 2020-08-18 | Kayyem Jon Faiz | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 3,396,101 | — | ↗ |
| 2020-08-18 | FORSYTH DOUGLAS | Director | — | I | Series Mezzanine 2 Preferred Stock | 82,422 | 0.00 | — | 0 | — | ↗ |
| 2020-08-18 | Eckelman Brendan P. | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 2,749,953 | — | ↗ |
| 2020-08-18 | Deveraux Quinn L. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 2,749,953 | — | ↗ |
| 2020-08-18 | Deck Kelly | Officer | — | D | Stock Option (right to buy) | 34,518 | 11.25 | 388.3K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-12.4K
Shares Outstanding
14.67M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Mark P. Lappe Chief Executive Officer and Chairman of the Board of Directors | 695.3K | 1.70M | — | — | 479.7K | 17.5K | 2.89M | 0.00% | ↗ |
| 2 | 2025 | David J. Matly, M.B.A. | 589.2K | — | — | 524.3K | 305.0K | 17.5K | 1.44M | 36.51% | ↗ |
| 3 | 2025 | Kelly D. Deck, C.P.A. Chief Financial Officer | 493.5K | — | — | 157.3K | 255.4K | 17.5K | 923.7K | 17.03% | ↗ |
| 4 | 2024 | Mark P. Lappe Chief Executive Officer and Chairman of the Board of Directors | 695.3K | — | — | 3.57M | 417.2K | 17.3K | 4.70M | 75.98% | ↗ |
| 5 | 2024 | Mark P. Lappe Chief Executive Officer and Chairman of the Board of Directors | 695.3K | — | — | 3.57M | 417.2K | 6.0K | 4.69M | 76.16% | ↗ |
| 6 | 2024 | Kelly D. Deck, C.P.A. Chief Financial Officer | 460.1K | 1.50M | — | 2.08M | 207.0K | 23.7K | 4.28M | 48.76% | ↗ |
| 7 | 2024 | Kelly D. Deck, C.P.A. Chief Financial Officer | 460.1K | 1.50M | — | 2.08M | 207.0K | 15.6K | 4.27M | 48.85% | ↗ |
| 8 | 2024 | Brendan P. Eckelman, Ph.D. Former Chief Scientific Officer | 535.6K | — | — | 2.08M | — | 7.5K | 2.63M | 79.33% | ↗ |
| 9 | 2023 | Mark P. Lappe Chief Executive Officer and Chairman of the Board of Directors | 675.0K | — | — | 1.71M | 405.0K | 15.3K | 2.80M | 60.91% | ↗ |
| 10 | 2023 | Brendan P. Eckelman, Ph.D. Former Chief Scientific Officer | 520.0K | — | — | 682.7K | 234.0K | 15.3K | 1.45M | 47.02% | ↗ |
| 11 | 2023 | Kelly D. Deck, C.P.A. Chief Financial Officer | 430.0K | — | — | 512.0K | 193.5K | 13.4K | 1.15M | 44.57% | ↗ |
| 12 | 2022 | Mark P. Lappe Chief Executive Officer and President | 650.0K | — | — | — | 357.5K | 15.3K | 1.02M | 0.00% | ↗ |
| 13 | 2022 | Kelly D. Deck, C.P.A. Chief Financial Officer | 380.0K | — | — | 491.3K | 133.0K | 18.2K | 1.02M | 48.05% | ↗ |
| 14 | 2022 | Brendan P. Eckelman, Ph.D. Chief Scientific Officer | 475.0K | — | — | — | 213.8K | 15.3K | 704.0K | 0.00% | ↗ |
| 15 | 2021 | Mark P. Lappe Chief Executive Officer and President | 650.0K | — | — | 3.69M | 325.0K | 19.3K | 4.68M | 78.76% | ↗ |
| 16 | 2021 | Klaus W. Wagner, M.D., Ph.D. Chief Medical Officer | 450.0K | — | — | 3.05M | 180.0K | 14.5K | 3.70M | 82.56% | ↗ |
| 17 | 2021 | Kelly D. Deck, C.P.A. Chief Financial Officer | 330.0K | — | — | 1.78M | 82.5K | 11.3K | 2.20M | 80.77% | ↗ |
| 18 | 2021 | Brendan P. Eckelman, Ph.D. Chief Scientific Officer | 450.0K | — | — | 1.02M | 180.0K | 14.5K | 1.66M | 61.22% | ↗ |
| 19 | 2020 | Klaus W. Wagner, M.D., Ph.D. Chief Medical Officer | 396.0K | — | — | 376.7K | 198.1K | 6.0K | 976.8K | 38.56% | ↗ |
| 20 | 2020 | Mark P. Lappe Chief Executive Officer and President | 530.0K | — | — | — | 331.5K | 7.5K | 869.0K | 0.00% | ↗ |
| 21 | 2020 | Brendan P. Eckelman, Ph.D. Chief Scientific Officer | 390.0K | — | — | — | 195.1K | 4.7K | 589.7K | 0.00% | ↗ |
| 22 | 2020 | Kelly D. Deck, C.P.A. Chief Financial Officer | 252.0K | — | — | 282.9K | 41.4K | 3.2K | 579.5K | 48.82% | ↗ |
| 23 | 2019 | Mark P. Lappe Chief Executive Officer and President | 450.0K | — | — | — | 225.0K | 189.0K | 864.0K | 0.00% | ↗ |
| 24 | 2019 | Brendan P. Eckelman, Ph.D. Chief Scientific Officer | 350.0K | — | — | — | 140.0K | 189.0K | 679.0K | 0.00% | ↗ |
| 25 | 2019 | Klaus W. Wagner, M.D., Ph.D. Chief Medical Officer | 360.0K | — | — | — | 144.0K | 14.0K | 518.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mark Paul Lappe | Founder, Chief Executive Officer & Chairman | 3M | male |
| David Matly | President | 911.7K | male |
| Kelly Devine Deck | Executive Vice President, Chief Financial Officer & Treasurer | 766.4K | female |
| Ashraf Amanullah | Executive Vice President & Chief Technical Operations Officer | — | — |
| Kate Burke | Vice President of Accounting | — | female |
| Leah Pollema | Vice President, General Counsel & Corporate Secretary | — | female |
| Josep Garcia | Executive Vice President & Chief Clinical Development Officer | — | — |
| Bonne Adams | Vice President of Operations | — | female |
| Carlos Bais | EVice President & Chief Scientific Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for INBX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
